Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

Completed

• Conditions: Cerebrotendinous Xanthomatoses

• Registration Number: NCT05499026
• Lead Sponsor: Leadiant Biosciences Ltd.

Brief Summary

Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid

Detailed Description

Not available

Study Timeline

• Study Start: 2014-12-09
• Primary Completion: 2015-06-03
• Study Completion: 2015-06-03
• Status Verified: 2022-08
• Study First Submitted: 2022-08-10
• Study First Submitted QC: 2022-08-10
• Last Update Submitted: 2022-08-10
• Study First Posted: 2022-08-12
• Last Update Posted: 2022-08-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Diagnosis of CTX Received treatment with CDCA Age between 2 and 75 years Having at least one cholestanol level and/or urinary bile alcohol level no more than 3 months prior to treatment with CDCA and one cholestanol level and/or urinary bile alcohol level post-treatment within 2 years from the beginning of therapy with CDCA

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Cholestanol Levels	34 years